In newly diagnosed AML, the presence of a TP53 mutation with VAF > 40% was independently associated with a significantly higher cumulative incidence of relapse and worse relapse-free and overall survival in patients treated with a cytarabine-based regimen. This evidence concerns the gene TP53 and acute myeloid leukemia.